Literature DB >> 17151505

Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.

Asheesh Tewari1, Mandeep S Dhalla, Rajendra S Apte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17151505     DOI： 10.1097/01.iae.0000254896.78766.74

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  16 in total

1.  Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Gulnar Hafiz; Diana V Do; Julia A Haller; Roberto Pili; Ingrid E Zimmer-Galler; Kashif Janjua; R C Andrew Symons; Peter A Campochiaro
Journal:  Am J Ophthalmol       Date:  2007-12-11       Impact factor: 5.258

2.  Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Authors:  Jose M Ruiz-Moreno; Javier A Montero; Pedro Amat-Peral
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

3.  Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length.

Authors:  Andrea Cacciamani; Francesco Oddone; Mariacristina Parravano; Fabio Scarinci; Marta Di Nicola; Giorgio Lofoco
Journal:  Jpn J Ophthalmol       Date:  2012-10-24       Impact factor: 2.447

4.  Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Noriaki Shimada; Muka Moriyama; Wakako Hara; Takeshi Yoshida; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-16       Impact factor: 3.117

5.  Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy.

Authors:  Ekta Rishi; Pukhraj Rishi; Sheshadri Mahajan
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

6.  Intravitreal bevacizumab: an analysis of the evidence.

Authors:  Derrick P Smit; David Meyer
Journal:  Clin Ophthalmol       Date:  2007-09

7.  Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-29       Impact factor: 3.117

8.  [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia].

Authors:  S Dithmar; K B Schaal; A E Höh; S Schmidt; F Schütt
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

Review 9.  The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.

Authors:  Nazimul Hussain; Yashoda Ghanekar; Inderjeet Kaur
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

10.  Off with the label and on the Avastin bandwagon: why now and how far?

Authors:  K S Santhan Gopal
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.